RT @jamesfomahony: Fantastic, succinct paper on the problems of transparency with the UK Cancer Drugs Fund by Eifiona Wood & @HughesDyfrig…
Not had the chance to read this yet but it sounds fascinating and my initial reaction is I couldn’t agree more. I found a similar direction of travel re:transparency across the appraisal programme as a whole. https://t.co/R894k8dY6V
RT @HughesDyfrig: Latest paper, on transparency concerns about the new Cancer Drugs Fund https://t.co/ueDWiCTBEf
Fantastic, succinct paper on the problems of transparency with the UK Cancer Drugs Fund by Eifiona Wood & @HughesDyfrig in PharmacoEconomics. I feel the moral legitimacy of life and death decisions within CEA is undermined when evidence is obscured.
RT @HughesDyfrig: Latest paper, on transparency concerns about the new Cancer Drugs Fund https://t.co/ueDWiCTBEf
RT @HughesDyfrig: Latest paper, on transparency concerns about the new Cancer Drugs Fund https://t.co/ueDWiCTBEf
RT @HughesDyfrig: Latest paper, on transparency concerns about the new Cancer Drugs Fund https://t.co/ueDWiCTBEf
RT @HughesDyfrig: Latest paper, on transparency concerns about the new Cancer Drugs Fund https://t.co/ueDWiCTBEf
Latest paper, on transparency concerns about the new Cancer Drugs Fund https://t.co/ueDWiCTBEf
#HealthEconJA The New and Non-Transparent Cancer Drugs Fund https://t.co/Q1rQdjdxOC